A
Aleksandra Eyring
Researcher at Johns Hopkins University
Publications - 7
Citations - 13613
Aleksandra Eyring is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pembrolizumab & DNA mismatch repair. The author has an hindex of 7, co-authored 7 publications receiving 10182 citations. Previous affiliations of Aleksandra Eyring include Merck & Co. & Ohio State University.
Papers
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le,Dung T. Le,Jennifer N. Durham,Jennifer N. Durham,Kellie N. Smith,Hao Wang,Bjarne Bartlett,Bjarne Bartlett,Laveet K. Aulakh,Laveet K. Aulakh,Steve Lu,Steve Lu,Holly Kemberling,Cara Wilt,Brandon Luber,Fay Wong,Fay Wong,Nilofer S. Azad,Agnieszka A. Rucki,Daniel A. Laheru,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Tim F. Greten,Austin G. Duffy,Kristen K. Ciombor,Aleksandra Eyring,Bao H. Lam,Andrew K. Joe,S. Peter Kang,Matthias Holdhoff,Ludmila Danilova,Leslie Cope,Christian F. Meyer,Shibin Zhou,Shibin Zhou,Richard M. Goldberg,Deborah K. Armstrong,Katherine M. Bever,Amanda N. Fader,Janis M. Taube,Franck Housseau,David Spetzler,Nianqing Xiao,Drew M. Pardoll,Nickolas Papadopoulos,Nickolas Papadopoulos,Kenneth W. Kinzler,Kenneth W. Kinzler,James R. Eshleman,Bert Vogelstein,Bert Vogelstein,Robert A. Anders,Robert A. Anders,Luis A. Diaz,Luis A. Diaz +57 more
TL;DR: Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).
Journal ArticleDOI
PD-1 blockade in tumors with mismatch repair deficiency.
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Nilofer S. Azad,Daniel A. Laheru,Ross C. Donehower,Brandon Luber,Todd S. Crocenzi,George A. Fisher,Steve M Duffy,James J. Lee,Minori Koshiji,James R. Eshleman,Robert A. Anders,Bert Vogelstein,Luis A. Diaz +19 more
TL;DR: MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Journal ArticleDOI
Programmed death-1 blockade in mismatch repair deficient colorectal cancer.
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Nilofer S. Azad,Daniel A. Laheru,Ross C. Donehower,Todd S. Crocenzi,Richard M. Goldberg,George A. Fisher,James J. Lee,Tim F. Greten,Minori Koshiji,Soonmo Peter Kang,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +19 more
TL;DR: The expanded trial and updated data for the mismatch repair deficient CRC (dMMR) and mismatch repair proficient CRC (pMMR, cohort B) cohorts are reported and pembrolizumab (pembro) was administered at 10 mg/kg every 14 days in patients with 2 or more prior therapies.
Journal ArticleDOI
PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.
Dung T. Le,Jennifer N. Uram,Hao Wang,Holly Kemberling,Aleksandra Eyring,Bjarne Bartlett,Richard M. Goldberg,Todd S. Crocenzi,George A. Fisher,James J. Lee,Tim F. Greten,Daniel A. Laheru,Nilofer S. Azad,Ross C. Donehower,Brandon Luber,Minori Koshiji,James R. Eshleman,Robert A. Anders,Bert Vogelstein,Luis A. Diaz +19 more
TL;DR: Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) will be reported in at least the first 17 patients with non-CRC gastrointestinal (GI) cancers.